Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients
Clinical trial NCT03663335 · COMPLETED
Trial details
- NCT number
- NCT03663335
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-28
- Primary completion
- 2021-10-29
- Enrollment
- 418
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.